1. Home
  2. NBIX vs H Comparison

NBIX vs H Comparison

Compare NBIX & H Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurocrine Biosciences Inc.

NBIX

Neurocrine Biosciences Inc.

HOLD

Current Price

$157.22

Market Cap

15.5B

Sector

Health Care

ML Signal

HOLD

Logo Hyatt Hotels Corporation

H

Hyatt Hotels Corporation

HOLD

Current Price

$163.71

Market Cap

16.8B

ML Signal

HOLD

Company Overview

Basic Information
Metric
NBIX
H
Founded
1992
1957
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Hotels/Resorts
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
15.5B
16.8B
IPO Year
1996
2009

Fundamental Metrics

Financial Performance
Metric
NBIX
H
Price
$157.22
$163.71
Analyst Decision
Strong Buy
Buy
Analyst Count
22
15
Target Price
$180.91
$179.53
AVG Volume (30 Days)
949.8K
627.7K
Earning Date
05-05-2026
04-30-2026
Dividend Yield
N/A
0.38%
EPS Growth
41.95
N/A
EPS
3.30
1.53
Revenue
$161,626,000.00
$4,685,000,000.00
Revenue This Year
$24.73
$110.63
Revenue Next Year
$13.14
$7.01
P/E Ratio
$47.34
$106.58
Revenue Growth
977.51
5.78
52 Week Low
$122.14
$134.18
52 Week High
$186.12
$206.86

Technical Indicators

Market Signals
Indicator
NBIX
H
Relative Strength Index (RSI) 52.22 35.83
Support Level $152.67 $157.88
Resistance Level $161.00 $172.76
Average True Range (ATR) 4.14 3.84
MACD 0.85 -0.62
Stochastic Oscillator 84.92 15.93

Price Performance

Historical Comparison
NBIX
H

About NBIX Neurocrine Biosciences Inc.

Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.

About H Hyatt Hotels Corporation

Hyatt is an operator of owned (2% of total rooms) and managed and franchised (98%) properties across about 35 upscale luxury brands, which include vacation brands (Apple Leisure Group, Hyatt Ziva, and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, the wellness brand Miraval, and the midscale extended-stay brand Studios. Hyatt acquired Two Roads Hospitality in 2018 and Apple Leisure Group in 2021. Regional exposure, as a percentage of total rooms, is 45% for the US, 31% for the rest of the world, and 24% for Asia-Pacific.

Share on Social Networks: